REDEFINING THE ENDGAME

摘要

Companies offering drug delivery technology have attempted in recent years to break away from the traditional business model of developing technology and licensing it to pharmaceutical firms for royalties generally ranging between 2 and 10% of sales. Most have added research, licensing, manufacturing, and marketing arms with the aim of upping revenues and, in some cases, transforming into pharmaceutical companies.